Page 5 - Informa Pharma Intelligence News Today

Minimizing Luck In Study Feasibility Part 1: Best Practices By Ashley Schwalje, Senior GTM Manager, Clinical R&D Strategy, Informa Pharma Intelligence and Daniel Chancellor, Thought Leadership Director, Informa Pharma Intelligence Two thirds of clinical trial sites are unable to meet original enrollment goals, with half of sites recruiting either a single patient or failing completely. Study sponsors must therefore scrutinize their current approaches to feasibility, as recruitment is such a cri...

View Comments When Johnson & Johnsons COVID-19 vaccine was authorized for use in late February, public health officials emphasized that it was just as good as the others. It was less effective, but because it requires only a single shot for full protection and is easier to distribute, it was a top choice for many people. Since then, the J&J vaccine has been given far less often than the other two authorized vaccines, accounting for one-tenth as many shots as Modernas vaccine, which is given ...

Understanding of Clinical Trials Up Among Americans Although vaccine hesitancy remains, levels of understanding have improved nearly two-fold following sentiments captured in Informa Pharma Intelligence’s 2020 Pulse Report when the COVID-19 vaccines had yet to be made available in the United States. 1 In fact, the percentage of Americans saying they’d be more likely to take a COVID-19 vaccine if they had more information on the clinical trials has dropped by half since 2020 (14% from 28%). ...

Understanding of Clinical Trials Up Among Americans Although vaccine hesitancy remains, levels of understanding have improved nearly two-fold following sentiments captured in Informa Pharma Intelligence’s 2020 Pulse Report when the COVID-19 vaccines had yet to be made available in the United States. 1 In fact, the percentage of Americans saying they’d be more likely to take a COVID-19 vaccine if they had more information on the clinical trials has dropped by half since 2020 (14% from 28%). ...

Informa Business Intelligence: While Over Three-Quarters of Americans Are Willing to Take at Least One of the Authorized COVID-19 Vaccines, Nearly a Quarter Are Still Hesitant as the U.S. Changes Course on Mitigation Strategy Understanding of Clinical Trials Up Among Americans Although vaccine hesitancy remains, levels of understanding have improved nearly two-fold following sentiments captured in Informa Pharma Intelligences 2020 Pulse Reportwhen the COVID-19 vaccines had yet to be made availa...

The vaccine money is in—and it’s pretty good. Pfizer reported revenue of $3.5 billion from its vaccine in the first quarter of 2021. Moderna sold $1.7 billion worth of vaccines in the same period, turning a profit for the first time in the company’s history. BioNTech, which is making the vaccine in partnership with Pfizer, expects $15 billion in vaccine sales this year (with an expected profit above 25%). AstraZeneca and Johnson & Johnson, meanwhile, are providing the shots on a not-for-p...

Author Bio Adria Cimino grew up with her nose in a book and a love of storytelling. By a twist of fate, she started her career writing about biotech in Boston and discovered that each company is the source of many fascinating stories. Prior to joining The Fool as a contract writer focused on healthcare and consumer goods, Adria covered the stock market for Bloomberg News in Paris. When she’s not analyzing companies, she can be found writing fiction or trying to speak F...

4 feb 2021 Skipta Donates Critical Online Media Support to U.S. COVID-19 Vaccine Education Campaign Contribution will help the Ad Council and COVID Collaborative amplify their national education effort for healthcare professionals in the U.S. around COVID-19 vaccine safety and effectiveness NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Skipta, part of Informa Pharma Intelligence and the leading social network of specialized online medical communities for verified healthcare professionals (HCPs)...

The new tests can open a window into the duration of immunity and to the antibody levels needed to sustain it. But first, a universal standard is needed to ensure results are comparable between tests.

Pandemic, Democratic Wins Leave Drug Industry at Crossroads Bloomberg 1/11/2021 Emma Court (Bloomberg) -- In 2020, the pharmaceutical industry raced to develop shots against a deadly new virus sweeping the globe -- and succeeded, in record time. They did it while navigating the pandemic themselves, managing operations and supply chains amid profound disruption. As the J.P. Morgan Healthcare Conference, the sector’s biggest annual gathering, kicks off virtually on Monday, dru...